According to the American Porphyria Foundation (APF), EPP and XLP combined are the third most common porphyria, with an incidence of possibly two to five per million people, and are the most ...

Since then, Alnylam has claimed approval for two more RNAis, Givlaari (givosiran) for acute hepatic porphyria (AHP) and Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1). RNAi uses small ...

Sverre Sandberg (born 1951) Head of the Norwegian Porphyria Centre (NAPOS), head of Norwegian Quality Improvement of Primary Health Care Laboratories outside hospitals (NOKLUS) and Professor at the ...